ATRACURIUM BESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for atracurium besylate and what is the scope of patent protection?
Atracurium besylate
is the generic ingredient in four branded drugs marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Norvium Bioscience, Teva Parenteral, Watson Pharms Teva, and Watson Labs Inc, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.There are sixteen drug master file entries for atracurium besylate. Three suppliers are listed for this compound.
Summary for ATRACURIUM BESYLATE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 11 |
| NDAs: | 23 |
| Drug Master File Entries: | 16 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 14 |
| Patent Applications: | 1,128 |
| What excipients (inactive ingredients) are in ATRACURIUM BESYLATE? | ATRACURIUM BESYLATE excipients list |
| DailyMed Link: | ATRACURIUM BESYLATE at DailyMed |
Recent Clinical Trials for ATRACURIUM BESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tanta University | N/A |
| Theodor Bilharz Research Institute | Phase 4 |
| Cairo University | Phase 4 |
Pharmacology for ATRACURIUM BESYLATE
| Drug Class | Nondepolarizing Neuromuscular Blocker |
| Physiological Effect | Neuromuscular Nondepolarizing Blockade |
Medical Subject Heading (MeSH) Categories for ATRACURIUM BESYLATE
Anatomical Therapeutic Chemical (ATC) Classes for ATRACURIUM BESYLATE
US Patents and Regulatory Information for ATRACURIUM BESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | TRACRIUM PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 018831-001 | Nov 23, 1983 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Baxter Hlthcare Corp | ATRACURIUM BESYLATE PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 074768-001 | Jan 23, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eugia Pharma | ATRACURIUM BESYLATE PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 206010-001 | Apr 8, 2015 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira Inc | ATRACURIUM BESYLATE | atracurium besylate | INJECTABLE;INJECTION | 090761-001 | Oct 18, 2012 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | ATRACURIUM BESYLATE PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 074639-001 | Mar 25, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Baxter Hlthcare | ATRACURIUM BESYLATE | atracurium besylate | INJECTABLE;INJECTION | 074824-001 | Sep 30, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norvium Bioscience | ATRACURIUM BESYLATE PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 206001-001 | Apr 7, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ATRACURIUM BESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hospira | TRACRIUM PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 018831-001 | Nov 23, 1983 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
